NDA 215064 · Chiesi
Filsuvez
Birch Triterpenes · Topical
NovelPriority reviewOrphanCDER novel approval, Dec 18, 2023: To treat wounds associated with dystrophic and junctional epidermolysis bullosa
Last checked: Nov 20, 2026Latest source record: Dec 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Dec 18, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
276
54 serious, 13 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 24, 2026.
FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older. FILSUVEZ topical gel is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older. ( 1 )
Mechanism: The mechanism of action of FILSUVEZ in the treatment of wounds associated with epidermolysis bullosa is unknown.
Therapeutic areas: Dermatology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 18, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
1 products under this application
- FILSUVEZ · BIRCH TRITERPENES 10% · GEL, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Birch Triterpenes" as an intervention, any sponsor and status, largest first.
- Filsuvez in Infants With Dystrophic or Junctional Epidermolysis BullosaNot yet recruiting
Medical University of South CarolinaAcademic, hospital or other
NCT07937748 · 20 participants (planned) · Start Jan 1, 2027 · Primary completion Jan 1, 2029
Drug: Filsuvez topical gel: 10% birch triterpenes · For: Dystrophic Epidermolysis Bullosa; Junctional Epidermolysis Bullosa
Sites: Charleston, South Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- wound complication43
- wound41
- product dose omission issue40
- product use issue38
- wrong technique in product usage process26
- drug ineffective25
- off label use24
- product administration interrupted24
- treatment noncompliance18
- blister17
- pruritus15
- wound secretion15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 53 |
| 2025 | 102 |
| 2026 | 121 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Filsuvez (Birch Bark Extract)
2024 spending
$1.6M
Beneficiaries
11
28 claims
Per beneficiary
$143,052
$78.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,573,576 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Filsuvez® (Birch Triterpenes) Topical Gel.
Gupta AK, Mann A, Vincent K, et al. · Skinmed 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.
Kern JS, Sprecher E, Fernandez MF, et al. · Br J Dermatol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Long-Term Efficacy and Safety of Oleogel-S10 (Birch Triterpenes) for Pediatric Patients With Epidermolysis Bullosa.
Sprecher E, Torres-Pradilla M, Fernandez MF, et al. · Pediatr Dermatol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Reduction in Dressing Change Burden in Patients With Epidermolysis Bullosa-Impact of Oleogel-S10.
Bruckner AL, Murrell D, Lee LW, et al. · J Dermatol 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Chiesi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.